Several other brokerages have also issued reports on GLPG. ValuEngine raised GALAPAGOS NV/S from a buy rating to a strong-buy rating in a research report on Thursday, April 4th. HC Wainwright upped their target price on GALAPAGOS NV/S to $150.00 and gave the company a positive rating in a research report on Friday, March 29th. Cantor Fitzgerald reaffirmed a buy rating and set a $130.00 target price on shares of GALAPAGOS NV/S in a research report on Thursday, May 2nd. Morgan Stanley upped their target price on GALAPAGOS NV/S from $138.00 to $139.00 and gave the company an overweight rating in a research report on Monday, April 29th. Finally, Zacks Investment Research lowered GALAPAGOS NV/S from a buy rating to a hold rating in a research report on Friday, March 1st. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $127.27.
Shares of NASDAQ:GLPG opened at $122.75 on Tuesday. GALAPAGOS NV/S has a 1 year low of $85.00 and a 1 year high of $125.48. The stock has a market cap of $6.29 billion, a P/E ratio of -185.98 and a beta of 1.52. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02.
Several hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN increased its holdings in shares of GALAPAGOS NV/S by 66.3% during the 1st quarter. Wells Fargo & Company MN now owns 1,678 shares of the biotechnology company’s stock worth $197,000 after purchasing an additional 669 shares during the period. Pinnacle Associates Ltd. bought a new position in shares of GALAPAGOS NV/S during the 1st quarter worth about $231,000. Vestmark Advisory Solutions Inc. bought a new position in shares of GALAPAGOS NV/S during the 1st quarter worth about $252,000. Townsquare Capital LLC bought a new position in shares of GALAPAGOS NV/S during the 4th quarter worth about $279,000. Finally, Comerica Bank increased its holdings in shares of GALAPAGOS NV/S by 6.3% during the 4th quarter. Comerica Bank now owns 3,120 shares of the biotechnology company’s stock worth $325,000 after purchasing an additional 185 shares during the period. 16.33% of the stock is currently owned by institutional investors and hedge funds.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Recommended Story: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.